Catalent pharma collaborate with Therachon for development of TA-46

Catalent Pharma Solutions announced that it has collaborated with Therachon AG to support preclinical and clinical development of TA-46. TA-46 is a novel protein addressing achondroplasia,  most common form of short-limbed dwarfism.

Under the agreement, Catalent Biologics has employed its proprietary GPEx® technology to produce different protein variants for Therachon, allowing them to screen multiple molecules and subsequently select their clinical candidate for further development.

Catalent Biologics VP and General Manager, Mike Riley said that the work being carried out by Therachon’s team is truly innovative and could have a significant impact for those diagnosed with achondroplasia and suffering the associated complications. The development work undertaken by Catalent Biologics to support Therachon’s outstanding research has the potential to bring this potentially life-changing product to the market as quickly as possible.

Catalent has been working with Therachon for more than a year to support the selection of the clinical candidate, and will now go on to manufacture cGMP material for a Phase I clinical study, scheduled for 2018. The project will be conducted at Catalent’s Madison, Wisconsin, biomanufacturing facility.